Regeneron Pharmaceuticals, Inc. (REGN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 1,150.56 |
| Open | 1,150.00 |
| Bid | 1,130.76 x 100 |
| Ask | 1,131.84 x 100 |
| Day's range | 1,128.97 - 1,152.87 |
| 52-week range | 769.19 - 1,211.20 |
| Volume | |
| Avg. volume | 457,875 |
| Market cap | 124.731B |
| Beta (5Y monthly) | 0.12 |
| PE ratio (TTM) | 29.93 |
| EPS (TTM) | 37.80 |
| Earnings date | 31 Oct 2024 - 04 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1,167.97 |
GuruFocus.comInsider Sale: Director Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc (REGN)
On September 3, 2024, Arthur Ryan, Director at Regeneron Pharmaceuticals Inc (NASDAQ:REGN), executed a sale of 100 shares of the company at a price of $1178.69 per share. This transaction was reported in a recent SEC Filing. Following this sale, the insider now owns 17,682 shares of Regeneron Pharmaceuticals Inc.
ZacksMerck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug
The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.
ZacksBiotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
Regeneron (REGN) and Lexicon (LXRX) are in the spotlight following drug approval and regulatory update, respectively.
© 2024 Yahoo. All rights reserved.